A Study of Olaratumab in Japanese Participants With Advanced Cancer
Status:
Completed
Trial end date:
2020-01-14
Target enrollment:
Participant gender:
Summary
This study consists of 2 parts (Part A and Part B). The main purpose of Part A is to evaluate
safety and side effects of olaratumab in combination with doxorubicin in Japanese
participants with a group of rare cancers (advanced solid tumors, especially advanced soft
tissue sarcoma [STS].) The main purpose of Part B is to evaluate how much olaratumab gets
into the blood stream of Japanese participants with advanced solid tumors and how long it
takes the body to get rid of it.